Padcev (Enfortumab Vedotin)

Enfortumab vedotin, the active ingredient in Padcev, is a antibody‑drug conjugate presented as a sterile powder for intravenous infusion use. It treats locally advanced or metastatic uro‑urinary tract cancer in adult patients who have received prior therapy. GNH USA supplies Padcev as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Padcev as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Padcev is an antibody‑drug conjugate that targets the Nectin‑4 pathway in uro‑thelial carcinoma.

- Metastatic urothelial carcinoma: improves survival and disease control in patients previously treated with chemotherapy and immunotherapy. - Locally advanced urothelial carcinoma: provides an additional therapeutic option after prior systemic therapy. - Post‑platinum therapy urothelial cancer: offers benefit where other regimens have failed. - Prior‑treatment urothelial carcinoma: extends treatment options after checkpoint inhibitor exposure.

Enfortumab   ??   ---